Fujifilm Diosynth Biotechnologies revealed that its CEO, Steve Bagshaw, would step down at the beginning of April to be replaced by the company’s chief operating officer, Martin Meeson.
Bagshaw has transitioned into the position of non-executive chairman after six years as head of the contract development and manufacturing organization. According to the company, Bagshaw decided to retire from the role.
Meeson will step into the role having accumulated 12 years of experience within the company, as he first began working at Fujifilm Diosynth as a director of finance before moving onto become SVP of global finance in 2013.
In 2015, Meeson became COO and, during this time, the company stated that he had been responsible for its ‘long-term gene therapy growth strategy’, which he previously discussed with BioPharma-Reporter.